Neurol. pro Praxi, 2006; 2: 114-116

Trazodon v neurologické praxi

prof. MUDr. Eva Češková, CSc.
Psychiatrická klinika LF MU a FN Brno

Deprese je nejčastější psychickou poruchou, která negativně ovlivňuje morbiditu a mortalitu somatických onemocnění. Řada biologických, psychologických a sociálních aspektů je zřejmě společná pro somatická a psychická onemocnění. Rozvoj antidepresiv byl velkým přínosem pro zkoumání etiopatogeneze deprese a pro léčbu deprese. Vývoj specifičtějších, bezpečnějších antidepresiv vedl k tomu, že jejich preskripce byla uvolněna pro lékaře prvního kontaktu a specialisty. Znalost mechanizmu účinku a dostupnost nových galenických forem vedla k obnovení zájmu o některé starší preparáty včetně trazodonu. Trazodon je specifické serotonergní antidepresivum charakterizované mírnou inhibicí zpětného vychytávání serotoninu a silnou blokádou serotoninových receptorů typu 5-HT 2A. V ČR je dostupný ve formě s pozvolným uvolňováním (Trittica AC). Kromě antidepresivního působení má anxiolytické vlastnosti a pozitivně ovlivňuje poruchy spánku včetně úpravy spánkové architektury. Tyto vlastnosti mohou být s výhodou uplatněny u depresí s převažující úzkostí a nespavostí.

Keywords: Klíčová slova: specifická antidepresiva, serotonin, trazodon, anxieta, insomnie.

Published: May 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Češková E. Trazodon v neurologické praxi. Neurol. praxi. 2006;7(2):114-116.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Anders M, Kitzlerová E. Trazodonum. Remedia 2004; 14: 452-463.
    2. Češková E. Koncept NDRI v léčbě deprese. Čes. a slov. Psychiatrie 2005; 101: 28-31.
    3. Gamble DE, Peterson LG. Trazodone overdose: four years of experience from voluntary reports. J Clin. Psychiatry 1986; 47: 544-6.
    4. Gillman PK. Serotonin syndrome history and risk. Fundamental Clin Pharmacol 1998; 12: 482-491. Go to original source... Go to PubMed...
    5. James SP, Mendelson WB. The use of trazodone as a hypnotic: a critical review. J Clin Psychiatry 2004; 65: 752-5. Go to original source... Go to PubMed...
    6. Kanner A M. Depression in epilepsy: Prevalence, clinical semiology, pathogenic mechanisms, and treatment. Biol Psychiatry 2003; 54: 388-398. Go to original source... Go to PubMed...
    7. Kasper S, Olivieri L, DiLoreto G, Dionisio P. A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder. Current Medical Research and Opinions 2005; 21: 1139-1146. Go to original source... Go to PubMed...
    8. Lippman S, Bedford P, Manshadi M, et al. Trazodone cardiotoxicity. Am J Psychiatry 1983; 140: 1 383.
    9. McDonald W M, Richard IH, DeLong MR. Prevalence, etiology, and treatment of depression in Parkinson's desease. Biol Psychiatry 2003; 54: 363-375. Go to original source... Go to PubMed...
    10. Melartin TK, Rytsala HJ, Leskla US, et al. Severity and comorbidity predict episode duration and recurrence of DSM-IV major depression. J Clin Psychiatry 2004; 65: 810-819. Go to original source... Go to PubMed...
    11. Náhunek K. Antidepressants: Their classification and efficacy in endogenous depression. J. E. Purkyne University Brno, Acta Facultatis Medicae Universitatis Brunensis; 1973.
    12. Nierenberg AA, Adler LA, Peselow E, et al. Trazodone for antidepressant-associated insomnia. Am J Psychiatry 1994; 151: 1069-72. Go to original source... Go to PubMed...
    13. Rickels K, Downing R, Schweizer E, et al. Antidepressants for the treatment of generalized anxiety disorders: a placebo controlled comparison with imipramine, trazodone and diazepam. Arch Gen Psychiatry 1993; 50: 884-95. Go to original source... Go to PubMed...
    14. Robertson MM. Suicide, parasuicide, and epilepsy. In: Engel J., Pedely TA, editors. Epilepsy: A comprehensive Textbook. Philadelphia., PA: Lippincott -Raven, 1997; 21451-2151.
    15. Robinson RG. Poststroke depression: prevalence, diagnosis, treatment, and disease progression. Biol Psychiatry 2003; 54: 376-387. Go to original source... Go to PubMed...
    16. Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P, et al. Insomnia in depression: differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 249-60. Go to original source... Go to PubMed...
    17. Schatzberg AF. Trazodone: a 5-year review of antidepressant efficacy. Psychopatology 20, 1987; 20 (Suppl. 1): 48-56. Go to original source... Go to PubMed...
    18. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. J Am Psychiatry 1965; 122: 509-514. Go to original source... Go to PubMed...
    19. Stahl SM. Essentials psychopharmacology. 2nd edition. Cambridge University Press, 2000.
    20. Stahl SM. At long last, long-lasting psychiatric medications: an overview of controlled-release technologies. J Clin Psychiatry 2003; 64: 355-356. Go to original source... Go to PubMed...
    21. Winkler D, Ordner R, Pjrek E, et al. Trazodone-induced cardiac arrhythmias: a report of two cases. Hum Psychopharmacol 2006; 21: 61-62. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.